InsiderTrades.com logo
Tomas J. Heyman net worth and biography
  • Phone
  • Email
  • Website

Tomas Heyman Biography and Net Worth

Director of Akero Therapeutics

Tom Heyman has a long-standing track record of leadership and management in the biopharmaceutical industry, with particular experience in business development and venture capital. Spanning his 37-year career with Johnson & Johnson, Tom held a diverse range of leadership roles across legal, R&D, business development, general corporate management and equity investments. Previously, he served as president of JJDC, the venture capital group within Johnson & Johnson, where he managed approximately $1.5 billion of capital and oversaw investments in over 120 companies. Prior to his time at JJDC, Mr. Heyman spent 23 years leading business development for Johnson & Johnson’s pharmaceutical group, Janssen. Tom currently serves on the Board of Directors of Adagio Therapeutics.

Tom graduated as Master of Law from the K.U. Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in business management at the University of Antwerp in Belgium.

How do I contact Tomas J. Heyman?

The corporate mailing address for Mr. Heyman and other Akero Therapeutics executives is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. Akero Therapeutics can also be reached via phone at (650) 487-6488 and via email at akero@sternir.com. Learn More on Tomas J. Heyman's contact information.

Has Tomas J. Heyman been buying or selling shares of Akero Therapeutics?

Tomas J. Heyman has not been actively trading shares of Akero Therapeutics during the past quarter. Learn More on Tomas J. Heyman's trading history.

Who are Akero Therapeutics' active insiders?

Akero Therapeutics' insider roster includes Kevin Bitterman (Director), Andrew Cheng (CEO), Tomas Heyman (Director), Patrick Lamy (SVP of Commercial Strategy ), Timothy Rolph (Co-Founder and Chief Scientific Officer), William White (CFO), Catriona Yale (Insider), and Jonathan Young (COO). Learn More on Akero Therapeutics' active insiders.

Are insiders buying or selling shares of Akero Therapeutics?

During the last twelve months, Akero Therapeutics insiders bought shares 1 times. They purchased a total of 200,000 shares worth more than $9,600,000.00. During the last twelve months, insiders at the sold shares 58 times. They sold a total of 969,114 shares worth more than $33,269,224.75. The most recent insider tranaction occured on March, 17th when insider Catriona Yale sold 10,000 shares worth more than $447,600.00. Insiders at Akero Therapeutics own 7.9% of the company. Learn More about insider trades at Akero Therapeutics.

Information on this page was last updated on 3/17/2025.

Tomas J. Heyman Insider Trading History at Akero Therapeutics

See Full Table

Tomas J. Heyman Buying and Selling Activity at Akero Therapeutics

This chart shows Tomas J. Heyman's buying and selling at Akero Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M$0$1MTotal Insider BuyingTotal Insider Selling

Akero Therapeutics Company Overview

Akero Therapeutics logo
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $42.67
Low: $41.84
High: $45.18

50 Day Range

MA: $44.85
Low: $22.31
High: $57.56

2 Week Range

Now: $42.67
Low: $17.86
High: $58.40

Volume

301,716 shs

Average Volume

805,876 shs

Market Capitalization

$3.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A